All In Biotech

Drug Trial Radar · NCT00249730

Titration Study to Evaluate Efficacy and Satisfaction of Viagra in Men With Erectile Function.

A Prospective Multicenter, Parallel Group Study With A Single Blind Phase And A Double Blind Randomised Phase, To Evaluate The Efficacy And Satisfaction Of Viagra (Sildenafil Citrate) High Dose (100mg) Titration Compared With 50mg Dose, In Men With Erectile Dysfunction

Last checked: Nov 19, 2026Latest source record: Feb 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 510 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

510

Actual

Start

Oct 2005

Primary completion

Not stated

Sponsor

Sponsor type
Industry
First posted
Nov 7, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy of Viagra dose titration to 100mg versus 50mg in men with erectile dysfunction, based on responses to the IIEF questionnaire as measured at the beginning and at the end of double blind treatment, comparing the group titrated to 100mg vs. the group maintained on 50mg.

Conditions

  • Impotence

Interventions

  • SildenafilDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in IIEF erectile function domain score at the end of double blind treatment.

Locations

39 sites in 8 countries. Site status is shown where the registry gives one.

  • Pfizer Investigational Site

    Kitchener, Ontario, Canada

  • Pfizer Investigational Site

    Sarnia, Ontario, Canada

  • Pfizer Investigational Site

    Toronto, Ontario, Canada

  • Pfizer Investigational Site

    Saint-Léonard, Quebec, Canada

  • Pfizer Investigational Site

    Trois-Rivières, Quebec, Canada

  • Pfizer Investigational Site

    Lille, France

  • Pfizer Investigational Site

    Lyon, France

  • Pfizer Investigational Site

    Montpellier, France

  • Pfizer Investigational Site

    Paris, France

  • Pfizer Investigational Site

    Pátrai, Greece

  • Pfizer Investigational Site

    Thessaloniki, Greece

  • Pfizer Investigational Site

    Goudi, Athens, Greece

  • Pfizer Investigational Site

    Beersheba, Israel

  • Pfizer Investigational Site

    Haifa, Israel

  • Pfizer Investigational Site

    Petah Tikva, Israel

  • Pfizer Investigational Site

    Tel Aviv, Israel

  • Pfizer Investigational Site

    Bologna, Italy

  • Pfizer Investigational Site

    Florence, Italy

  • Pfizer Investigational Site

    L’Aquila, Italy

  • Pfizer Investigational Site

    Milan, Italy

  • Pfizer Investigational Site

    Roma, Italy

  • Pfizer Investigational Site

    Moscow, Russia

  • Pfizer Investigational Site

    Alicante, Spain

  • Pfizer Investigational Site

    Barcelona, Spain

  • Pfizer Investigational Site

    Madrid, Spain

  • Pfizer Investigational Site

    Málaga, Spain

  • Pfizer Investigational Site

    Seville, Spain

  • Pfizer Investigational Site

    Valencia, Spain

  • Pfizer Investigational Site

    San Cristóbal de La Laguna, Santa Cruz De Tenerife, Spain

  • Pfizer Investigational Site

    Bath, United Kingdom

  • Pfizer Investigational Site

    Coventry, United Kingdom

  • Pfizer Investigational Site

    Doncaster, United Kingdom

  • Pfizer Investigational Site

    Dundee, United Kingdom

  • Pfizer Investigational Site

    Glasgow, United Kingdom

  • Pfizer Investigational Site

    Belmont, Durham, United Kingdom

  • Pfizer Investigational Site

    Ashford, Middlesex, United Kingdom

  • Pfizer Investigational Site

    Weybridge, Surrey, United Kingdom

  • Pfizer Investigational Site

    Chippenham, Wilts., United Kingdom

  • Pfizer Investigational Site

    Trowbridge, Wiltshire, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.